Satellite Symposia

Satellite symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information.  

Thursday, May 3

Satellite Symposium - Pfizer Oncology (18:30 - 20:00)

Management of Patients with ER + HER2 - Metastatic Breast Cancer

Xinni Song, Assistant Professor of Medicine, University of Ottawa, Division of Medical Oncology, Ottawa, ON

Learning Objectives:

  • Treating ER+ HER2- MBC patients –a review of the treatment guidelines;
  • The role of the multidisciplinary healthcare team in the management of patients with ER+ MBC; and
  • Clinical use  of the CDK 4/6 inhibitors– case based discussion on dose, monitoring requirement and side effect management.

Friday, May 4

Satellite Symposium - Apobiologix (07:00 - 08:30)

The Science Behind Biosimilars

The value that biosimilars bring to the healthcare system is their potential to provide significant cost savings thereby contributing to sustainability and accessibility. Realizing this potential is, in large part, dependent upon how well biosimilars are understood by healthcare providers, patients and payers. Significant advances in technology, analytics and manufacturing of biologic medicines has kept pace over the decades. This symposium will take a deeper dive into the science behind biosimilars focusing on how these advances have been applied to the development of biosimilar medicines.

Satellite Symposium - Amgen (08:45-10:15)

Optimizing the Opportunity: What the Pharmacist Needs to Know About Therapeutic Biosimilars in Oncology

The introduction of therapeutic biosimilars represents another step forward in providing more lifesaving treatment options to patients with cancer.
Oncology healthcare professionals will soon be faced with new decisions as they adopt therapeutic biosimilars into the solid tumour treatment armamentarium.
 
Learning Objectives:
  • Compare and contrast the development process for generic drugs and oncology therapeutic biosimilars;
  • Examine the scientific evidence and regulatory requirements for marketing authorization of oncology therapeutic biosimilars; and
  • Explore clinical considerations and practical issues associated with day-to-day choices related to oncology therapeutic biosimilars.

Satellite Symposium - AstraZeneca (10:30 - 12:00)

Practice Update: Locally Advanced Non-Small Cell Lung Cancer

This is a multidisciplinary education program for healthcare professionals involved in care of patients with locally advanced non-small cell lung cancer (NSCLC).

Learning Objectives:
  • Recognize unmet needs in locally advanced NSCLC;
  • Support evidence-based treatment decisions; and
  • Create awareness of future developments that may influence patient care.

Satellite Symposium - Astellas (12:15 - 13:45)

Satellite Symposium - Ipsen(14:00 - 15:30)

Optimizing Outcomes for Patients with Rare Cancers: The Neuroendocrine Tumors (NET’s) Patient Journey

Neuroendocrine tumours or NETs are a group of uncommon tumours that develop in the cells of the neuroendocrine system, throughout the body. Patients with NETs  do not have  a clear path of care in their cancer journey, therefore the multidisciplinary team approach is important to providing support and building patient and family resilience.

Learning Objectives:
  • Gain a deeper understanding of the NETs journey from the patient perspective;
  • Review the treatment options for patients with NETs; and
  • Discuss the role of the multi-disciplinary team with a focus on the role of the pharmacist.

Satellite Symposium - Hoffmann - La Roche (15:45 - 17:15)

 

Saturday, May 5

Satellite Symposium - BD Canada (07:00 - 08:30)

Panel discussion: Implementing Effective Strategies to Manage New Drug Waste Costs When Complying With the Beyond Use Dating Requirements of the NAPRA Model Standards.

Panelists: 
Rick Abbott, Eastern Health, St. John's, NL
Lindsey Amerine, University of North Carolina (UNC) Medical Center, Chapel Hill, NC
Lily Spasic, Stronach Regional Cancer Centre, Newmarket, ON
Alicia Wall, Dr. H. Bliss Murphy Cancer Center and Health Sciences Center, St. John's, NL
 
Facilitator: Marshall Moleschi, Retired BC and Ontario Registrar, Toronto, ON

Based on the published NAPRA Model Standards for Hazardous Drug Compounding, it is anticipated that Canadian pharmacies will be required to discard single-dose drug vials 6 hours following first puncture. This is a change in practice that will have a significant impact on budgets, increasing the costs of drug wastage. Therefore finding strategies to manage these new drug waste costs is key to many Canadian pharmacies. This symposium will provide a review of these requirements, and how two institutions have achieved significant savings by using Closed System Transfer Devices to prevent microbial ingress and extend the life of the vial.

Learning Objectives:
  • A review of the new NAPRA Beyond Use Dating requirements for single-dose vials;
  • A review of a large US institution’s approach to optimizing single dose vials;
  • A Canadian approach to optimizing single dose vials and preventing waste; and
  • A practical approach to initiating sterility testing.  

Sunday, May 6

Satellite Symposium - Janssen (07:00 - 08:30)

Satellite Symposium - Purdue(12:30 - 14:00)